Pharvaris NV (NASDAQ:PHVS) has completed the enrollment in CHAPTER 3 study of deucrictibant XR (extended release) for HAE (hereditary angioedema).

If the topline data, scheduled for the third quarter of 2026, is positive, it would make the company "the first, one stop shop for all things HAE," according to Guggenheim Securities.

The Pharvaris Analyst: Analyst Debjit Chattopadhyay maintained a Buy rating and price target of $39.

The Pharvaris Thesis: The probability of success is around 70%, Chattopadhyay said in the note.

Check out other analyst stock ratings.

Data indicate that a 40 mg daily dose of the extended-release (XR) tablet keeps drug levels in the blood 2–6 times higher than the necessary threshold (EC85) to prevent attacks, he added.

If the trial shows more than 80% reduction in monthly attacks, the drug could offer a potential 30% upside for Pharvaris' share price, the analyst stated. 

PHVS Price Action: Pharvaris shares were down 0.14% at $28.52 at the time of publication on Monday, according to Benzinga Pro data.

Photo: Gorodenkoff/Shutterstock